268 related articles for article (PubMed ID: 20713596)
21. Combination of neutralizing monoclonal antibodies against Hepatitis C virus E2 protein effectively blocks virus infection.
Bose M; Mullick R; Das S; Das S; Karande AA
Virus Res; 2016 Sep; 224():46-57. PubMed ID: 27574733
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of HCV 3a genotype entry through host CD81 and HCV E2 antibodies.
Ashfaq UA; Qasim M; Yousaf MZ; Awan MT; Jahan S
J Transl Med; 2011 Nov; 9():194. PubMed ID: 22074322
[TBL] [Abstract][Full Text] [Related]
23. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.
Fofana I; Krieger SE; Grunert F; Glauben S; Xiao F; Fafi-Kremer S; Soulier E; Royer C; Thumann C; Mee CJ; McKeating JA; Dragic T; Pessaux P; Stoll-Keller F; Schuster C; Thompson J; Baumert TF
Gastroenterology; 2010 Sep; 139(3):953-64, 964.e1-4. PubMed ID: 20685314
[TBL] [Abstract][Full Text] [Related]
24. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
[TBL] [Abstract][Full Text] [Related]
25. [Novel strategies for preventing viral hepatitis C recurrence after liver transplantation].
Stoll-Keller F; Fafi-Kremer S; Wolf P; Doffoël M; Baumert T
Bull Acad Natl Med; 2008 Nov; 192(8):1657-67; discussion 1667-8. PubMed ID: 19445379
[TBL] [Abstract][Full Text] [Related]
26. An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission.
Tarr AW; Lafaye P; Meredith L; Damier-Piolle L; Urbanowicz RA; Meola A; Jestin JL; Brown RJ; McKeating JA; Rey FA; Ball JK; Krey T
Hepatology; 2013 Sep; 58(3):932-9. PubMed ID: 23553604
[TBL] [Abstract][Full Text] [Related]
27. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.
Lin LT; Chung CY; Hsu WC; Chang SP; Hung TC; Shields J; Russell RS; Lin CC; Li CF; Yen MH; Tyrrell DL; Lin CC; Richardson CD
J Hepatol; 2015 Mar; 62(3):541-8. PubMed ID: 25450204
[TBL] [Abstract][Full Text] [Related]
28. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
[TBL] [Abstract][Full Text] [Related]
29. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection.
Osburn WO; Fisher BE; Dowd KA; Urban G; Liu L; Ray SC; Thomas DL; Cox AL
Gastroenterology; 2010 Jan; 138(1):315-24. PubMed ID: 19782080
[TBL] [Abstract][Full Text] [Related]
30. Interferon-Induced Transmembrane Proteins Mediate Viral Evasion in Acute and Chronic Hepatitis C Virus Infection.
Wrensch F; Ligat G; Heydmann L; Schuster C; Zeisel MB; Pessaux P; Habersetzer F; King BJ; Tarr AW; Ball JK; Winkler M; Pöhlmann S; Keck ZY; Foung SKH; Baumert TF
Hepatology; 2019 Nov; 70(5):1506-1520. PubMed ID: 31062385
[TBL] [Abstract][Full Text] [Related]
31. Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies.
Das S; Mullick R; Kumar A; Tandon H; Bose M; Gouthamchandra K; Chandra M; Ravishankar B; Khaja MN; Srinivasan N; Das S; Melkote Subbarao S; Karande AA
J Gen Virol; 2017 May; 98(5):962-976. PubMed ID: 28221101
[TBL] [Abstract][Full Text] [Related]
32. Binding of hepatitis C virus to CD81.
Pileri P; Uematsu Y; Campagnoli S; Galli G; Falugi F; Petracca R; Weiner AJ; Houghton M; Rosa D; Grandi G; Abrignani S
Science; 1998 Oct; 282(5390):938-41. PubMed ID: 9794763
[TBL] [Abstract][Full Text] [Related]
33. Functional Behavior of NKp46-Positive Intrahepatic Natural Killer Cells Against Hepatitis C Virus Reinfection After Liver Transplantation.
Tanimine N; Tanaka Y; Abe T; Piao J; Chayama K; Ohdan H
Transplantation; 2016 Feb; 100(2):355-64. PubMed ID: 26714120
[TBL] [Abstract][Full Text] [Related]
34. Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization.
Vercauteren K; Mesalam AA; Leroux-Roels G; Meuleman P
World J Gastroenterol; 2014 Nov; 20(43):15975-91. PubMed ID: 25473151
[TBL] [Abstract][Full Text] [Related]
35. Analysis of a conserved RGE/RGD motif in HCV E2 in mediating entry.
Rothwangl KB; Rong L
Virol J; 2009 Jan; 6():12. PubMed ID: 19171049
[TBL] [Abstract][Full Text] [Related]
36. Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.
Lavie M; Sarrazin S; Montserret R; Descamps V; Baumert TF; Duverlie G; Séron K; Penin F; Dubuisson J
J Virol; 2014 Sep; 88(18):10584-97. PubMed ID: 24990994
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C.
Steinmann D; Barth H; Gissler B; Schürmann P; Adah MI; Gerlach JT; Pape GR; Depla E; Jacobs D; Maertens G; Patel AH; Inchauspé G; Liang TJ; Blum HE; Baumert TF
J Virol; 2004 Sep; 78(17):9030-40. PubMed ID: 15308699
[TBL] [Abstract][Full Text] [Related]
38. A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I.
Zuiani A; Chen K; Schwarz MC; White JP; Luca VC; Fremont DH; Wang D; Evans MJ; Diamond MS
J Virol; 2016 Dec; 90(23):10499-10512. PubMed ID: 27630236
[TBL] [Abstract][Full Text] [Related]
39. Mice Expressing Minimally Humanized CD81 and Occludin Genes Support Hepatitis C Virus Uptake In Vivo.
Ding Q; von Schaewen M; Hrebikova G; Heller B; Sandmann L; Plaas M; Ploss A
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928007
[TBL] [Abstract][Full Text] [Related]
40. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.
Lupberger J; Zeisel MB; Xiao F; Thumann C; Fofana I; Zona L; Davis C; Mee CJ; Turek M; Gorke S; Royer C; Fischer B; Zahid MN; Lavillette D; Fresquet J; Cosset FL; Rothenberg SM; Pietschmann T; Patel AH; Pessaux P; Doffoël M; Raffelsberger W; Poch O; McKeating JA; Brino L; Baumert TF
Nat Med; 2011 May; 17(5):589-95. PubMed ID: 21516087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
